RBM Achieves Milestone in Companion Diagnostic Project with Roche
May 27, 2011
RBM Achieves Milestone in Companion Diagnostic Project with Roche
Using its DiscoveryMAP protein biomarker discovery platform, the company identified a biomarker pattern useful in monitoring disease progression and predicting and monitoring the efficacy of a compound in Roche's CNS pipeline.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 3, 2011 / ProteoMonitor - Myriad to Enter Proteomics Market with $80M Purchase of Rules-Based Medicine
April 29, 2011 / ProteoMonitor - Myriad Highlights RBM Pharma Work, Reports $2M in Q4 Revenues from Companion Diagnostics
August 12, 2011 / ProteoMonitor - TARC Team Uses RBM's DiscoveryMAP Platform to Develop Alzheimer's Protein-Biomarker Test
September 17, 2010 / ProteoMonitor - ADNI Researchers and Industry Partners Developing Proteomic Profiles to Track Alzheimer's Disease
June 11, 2010 / ProteoMonitor